Building the evidence base for shortened MDR-TB treatment regimens

Affiliations

¹ International Union Against Tuberculosis and Lung Disease Paris, France, Division of Research and Development, Vital Strategies New York, NY, USA, Dalla Lana School of Public Health, University of Toronto Toronto, ON, Canada.
² International Union Against Tuberculosis and Lung Disease Paris, France, Division of Pulmonary Medicine, Department of Internal Medicine Wan Fang Hospital, Taipei Medical University, Division of Pulmonary Medicine, Department of Internal Medicine School of Medicine, College of Medicine Taipei Medical University, Taipei, Taiwan <email></email> <email>cychiang@theunion.org</email>, Email: irusen@theunion.org.

Editorial

I D Rusen et al. Int J Tuberc Lung Dis. 2018.

. 2018 Jan 1;22(1):1-2.

doi: 10.5588/ijtld.17.0776.

¹ International Union Against Tuberculosis and Lung Disease Paris, France, Division of Research and Development, Vital Strategies New York, NY, USA, Dalla Lana School of Public Health, University of Toronto Toronto, ON, Canada.
² International Union Against Tuberculosis and Lung Disease Paris, France, Division of Pulmonary Medicine, Department of Internal Medicine Wan Fang Hospital, Taipei Medical University, Division of Pulmonary Medicine, Department of Internal Medicine School of Medicine, College of Medicine Taipei Medical University, Taipei, Taiwan <email></email> <email>cychiang@theunion.org</email>, Email: irusen@theunion.org.

No abstract available

Comment on

Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries.
Trébucq A, Schwoebel V, Kashongwe Z, Bakayoko A, Kuaban C, Noeske J, Hassane S, Souleymane B, Piubello A, Ciza F, Fikouma V, Gasana M, Ouedraogo M, Gninafon M, Van Deun A, Cirillo DM, Koura KG, Rieder HL. Trébucq A, et al. Int J Tuberc Lung Dis. 2018 Jan 1;22(1):17-25. doi: 10.5588/ijtld.17.0498. Epub 2017 Nov 17. Int J Tuberc Lung Dis. 2018. PMID: 29149917